Patents Assigned to Emory University
  • Patent number: 10933169
    Abstract: The disclosure relates to compounds and compositions for bone formation, fracture treatment, bone grafting, bone fusion, cartilage maintenance and repair, and methods related thereto. In certain embodiments, the disclosure relates to compositions comprising one or more compound(s) disclosed herein derivatives, or salt thereof, for use in bone growth processes. In a typical embodiment, a bone graft composition is implanted in a subject at a site of desired bone growth or enhancement. In certain embodiments, compounds disclosed herein are useful for managing obesity and diabetes or other metabolic syndromes by modulation of brown fat.
    Type: Grant
    Filed: September 6, 2019
    Date of Patent: March 2, 2021
    Assignee: Emory University
    Inventors: Scott D. Boden, Sreedhara Sangadala
  • Patent number: 10937523
    Abstract: Methods, systems and computer-readable storage media relate to generating one or more consensus sequences. The methods may include determining a group of one or more reads with each main position without diversity from a group of one or more aligned reads based on diversity status of each main position, each group including sequence data disposed at a plurality of main positions and a plurality of secondary position regions disposed adjacent to the main positions. The methods may also include determining legitimate sequence data from each second position region having one or more nucleotides for each group of one or more reads without diversity; and generating a consensus sequence including sequence data disposed at each main position without diversity and legitimate sequence data disposed at each secondary position region for each group of one or more reads with each main position without diversity.
    Type: Grant
    Filed: August 27, 2015
    Date of Patent: March 2, 2021
    Assignee: Emory University
    Inventors: Dario A. Dilernia, Jung-Ting Chien, Eric Hunter
  • Publication number: 20210056697
    Abstract: The systems and methods can accurately and efficiently determine a myocardial risk from a lesion disposed along a coronary segment using hemodynamic characteristic(s) associated with one or more sections of the corresponding lesion site. The method may include segmenting one or more lesion sites disposed along at least one arterial segment of the one or more arterial segments of the coronary model into one or more sections. Each lesion site includes a lesion. The method may include determining one or more characteristics for at least one section using at least the one or more characteristics associated with the at least one arterial segment. The one or more characteristics for the at least one section including hemodynamic force characteristic(s) (e.g., wall shear stress (WSS)). The method may include determining one or more risk indices for each lesion site using at least the hemodynamic force characteristic(s) for the at least one section.
    Type: Application
    Filed: March 11, 2019
    Publication date: February 25, 2021
    Applicant: Emory University
    Inventors: Habib SAMADY, Alessandro VENEZIANI, Don GIDDENS, David MOLONY, Adrien LEFIEUX, Arnav KUMAR
  • Patent number: 10927119
    Abstract: Certain pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds that inhibit cycline dependent kinase (CDK) (e.g., CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDK10, CDK11, CDK12, CDK13, etc.) are disclosed. Pharmaceutical compositions comprising these compounds, and the use of these compounds and compositions to inhibit CDK; to treat disorders associated with CDK such as those arising from an inappropriate activity, mutation, overexpression, or upstream pathway activation of CDK; or disorders that are ameliorated by the inhibition of CDK; proliferative disorders; cancer; viral infections; neurodegenerative disorders; ischaemia; renal diseases; and cardiovascular disorders are also disclosed. Optionally, the treatment further comprises simultaneous or sequential treatment with a further active agent, e.g., an aromatase inhibitor, an anti-estrogen, a Her2 blocker, a cytotoxic chemotherapeutic agent, etc.
    Type: Grant
    Filed: September 4, 2019
    Date of Patent: February 23, 2021
    Assignees: IP2IPO Innovations Limited, Emory University, Cancer Research Technology Limited
    Inventors: Alexander Bondke, Sebastian Kroll, Anthony Barrett, Matthew Fuchter, Brian Slafer, Simak Ali, Charles Coombes, James Patrick Snyder
  • Patent number: 10919934
    Abstract: This disclosure relates to compositions for use in managing respiratory distress and related disorders. In certain embodiments, the disclosure relates to methods of treating or preventing respiratory distress comprising administering an effective amount of a pharmaceutical composition comprising peptides or agents disclosed herein to a subject in need thereof. In certain embodiments, the peptides or agents decrease the concentration of claudin-5 in cells and tissues of the lungs.
    Type: Grant
    Filed: July 7, 2020
    Date of Patent: February 16, 2021
    Assignee: Emory University
    Inventors: Michael Koval, Barbara Schlingmann
  • Patent number: 10905710
    Abstract: This disclosure relates to nucleobase polymers useful for degrading GATA-3 mRNA. In certain embodiments, this disclosure relates to nucleobase polymers and nanoparticles conjugated to nucleobase polymers disclosed herein. In certain embodiments, the nucleobase polymers or nanoparticles can be used in methods of managing disorders associated with excessive GATA-3 expression in inflammatory disorders and respiratory disorders such as asthma.
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: February 2, 2021
    Assignees: Emory University, The United States Government as represented by the Department of Veterans Affairs
    Inventors: Khalid Salaita, Cherry Wongtrakool, Kornelia Galior
  • Patent number: 10905586
    Abstract: Methods and devices are provided for targeted administration of a drug to a patient's eye. In one embodiment, the method includes inserting a hollow microneedle into the sclera of the eye at an insertion site and infusing a fluid drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused fluid drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. The fluid drug formulation may flow circumferentially toward the retinochoroidal tissue, macula, and optic nerve in the posterior segment of the eye.
    Type: Grant
    Filed: March 23, 2020
    Date of Patent: February 2, 2021
    Assignees: Georgia Tech Research Corporation, Emory University
    Inventors: Mark Prausnitz, Henry F. Edelhauser, Samirkumar Rajnikant Patel
  • Patent number: 10900069
    Abstract: This disclosure related to methods of detecting mechanical forces required to separate ligand and receptor interactions. In certain embodiments, this disclosure relates to methods of detecting mechanical forces between a ligand and receptor, where the ligand is immobilized on a surface using weaker forces. Ligand-receptor forces lead to dissociation of the ligand that can be detected and amplified. In certain embodiments, the disclosure relates to methods of detecting ligand and receptor interactions comprising linking a ligand to one of two binding partners, wherein the binding partners have attracting forces that are less than the forces between the ligand and a receptor of the ligand such that when the ligand binds the receptor, the binding partners will separate. Separation of the binding partners can be detected.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: January 26, 2021
    Assignee: Emory University
    Inventors: Khalid Salaita, Pui-yan Ma
  • Patent number: 10898588
    Abstract: Disclosed herein are recombinant viral vectors comprising a liver specific promotor in operable combination with a heterologous nucleic acid sequence encoding a protein, such as a clotting factor. Methods of treating a subject with a clotting disorder, such as hemophilia A or hemophilia B, are also provided.
    Type: Grant
    Filed: August 8, 2018
    Date of Patent: January 26, 2021
    Assignees: Emory University, Children's Healthcare of Atlanta, Inc.
    Inventors: Christopher B. Doering, H. Trent Spencer, Harrison C. Brown
  • Patent number: 10888565
    Abstract: The disclosure relates to compounds and compositions for forming bone and methods related thereto. In one embodiment, the disclosure relates to a composition comprising a compound disclosed herein, such as 2,4-diamino-1,3,5-triazine derivatives or salts thereof, for use in bone growth processes. In a typical embodiment, a bone graft composition is implanted in a subject at a site of desired bone growth or enhancement.
    Type: Grant
    Filed: January 2, 2020
    Date of Patent: January 12, 2021
    Assignees: Emory University, The United States Government as represented by the Department of Veterans Affairs
    Inventors: Scott D. Boden, Sreedhara Sangadala
  • Patent number: 10889628
    Abstract: This disclosure relates to recombinant proteins, vectors, and methods of treating neurological conditions by exposing neurons to an opsin and luciferase in the presence of a luciferin. In certain embodiments, the disclosure relates to treating or preventing epilepsy or seizures comprising administering an effective amount of a vector that encodes an opsin and luciferase in combination with a luciferin to a subject in need thereof.
    Type: Grant
    Filed: February 12, 2018
    Date of Patent: January 12, 2021
    Assignee: Emory University
    Inventors: Robert E. Gross, Nealen G. Laxpati, Jack Tung, Ken Berglund
  • Patent number: 10874683
    Abstract: This disclosure relates to certain N4-hydroxycytidine derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of a Zika virus infection.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: December 29, 2020
    Assignee: Emory University
    Inventors: George R. Painter, David B. Guthrie, Gregory R. Bluemling, Michael R. Natchus
  • Patent number: 10866291
    Abstract: Devices and systems can be configured to guide an instrument to a target region. The guide system may include an imaging guide including a first segment, the first segment including a guide region and imaging coils surrounding the guide region; and a platform. The platform may include a first rail, a second rail disposed parallel to the first rail, and a positioning member disposed between the first rail and the second rail. The positioning member may include a positioning frame having an entry region. The positioning frame may be movably disposed with respect to the first and second rails in a first direction and a second direction that is perpendicular to the first direction. The platform may be disposed with respect to the imaging guide so that a position of the entry region is within the guide region.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: December 15, 2020
    Assignee: Emory University
    Inventors: Nicholas M. Boulis, John N. Oshinski, Jason J. Lamanna, Cody Dillion Anderson
  • Patent number: 10849652
    Abstract: Devices, systems and methods are provided for enhancing mechanical strength of tissue, allowing direct and secure access to cardiac and vascular structures, either through tiny incisions or percutaneously. The method for accessing a cardiac chamber or a vascular conduit may include providing an access channel into tissue of the chamber or the conduit. The method may also include providing an energy-transducing element configured to provide heat within the access channel. The method may further include applying energy to the tissue or a tissue-stabilizing composition injected into, around, or adjacent to the tissue to mechanically enhance the access channel.
    Type: Grant
    Filed: April 27, 2016
    Date of Patent: December 1, 2020
    Assignee: Emory University
    Inventors: Robert A. Guyton, Saimuralidhar Padala
  • Patent number: 10843996
    Abstract: This disclosure relates to modulators of liver receptor homologue 1 (LRH-1) and methods of managing disease and conditions related thereto. In certain embodiments, modulators are derivatives of hexahydropentalene. In certain embodiments, this disclosure relates to methods of treating or preventing cancer, diabetes, or cardiovascular disease by administering an effective amount of a hexahydropentalene derivative disclosed herein.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: November 24, 2020
    Assignee: Emory University
    Inventors: Eric Ortlund, Suzanne Mays, Nathan Jui, Autumn Flynn, Michael Dugan
  • Patent number: 10828331
    Abstract: This disclosure relates to compounds, compositions and methods of epigenetically transforming cells. In certain embodiments, the disclosure relates to methods of generating epigenetically altered cells comprising mixing isolated cells with compositions disclosed herein under conditions such that epigenetically altered cells are formed. In certain embodiments, methods of treating or preventing vascular or diabetic diseases or conditions are contemplated. In certain embodiments, epigenetically reprogramming adult bone marrow-derived stem or progenitor cells including mesenchymal stem cells (MSCs) or endothelial progenitor cells (EPCs) for autologous treatments are contemplated.
    Type: Grant
    Filed: February 23, 2017
    Date of Patent: November 10, 2020
    Assignee: Emory University
    Inventors: Young-Sup Yoon, Ji Woong Han
  • Patent number: 10821111
    Abstract: Compounds, compositions, and methods of treatment and prevention of HIV infection are disclosed. The compounds are pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidine JAK inhibitors. Combinations of these JAK inhibitors and additional antiretroviral compounds, such as NRTI, NNRTI, integrase inhibitors, entry inhibitors, protease inhibitors, and the like, are also disclosed. In one embodiment, the combinations include a combination of adenine, cytosine, thymidine, and guanine nucleoside antiviral agents, optionally in further combination with at least one additional antiviral agent that works via a different mechanism than a nucleoside analog. This combination has the potential to eliminate the presence of HIV in an infected patient.
    Type: Grant
    Filed: July 16, 2018
    Date of Patent: November 3, 2020
    Assignee: Emory University
    Inventors: Christina Gavegnano, Raymond F. Schinazi
  • Publication number: 20200323903
    Abstract: The present disclosure is generally related to methods for combining chemotherapy and immunotherapy for the treatment of a cancer.
    Type: Application
    Filed: December 9, 2019
    Publication date: October 15, 2020
    Applicants: Emory University, The UAB Research Foundation, Children's Healthcare of Atlanta, Inc.
    Inventors: Harold Trent Spencer, Anindya Dasgupta, Lawrence S. Lamb
  • Patent number: 10792274
    Abstract: This disclosure relates to methods of managing or treating cancer with agents that lower circulating acetoacetate levels, such as hypolipidemic agents, or other agents that antagonize acetoacetate-BRAF V600 mutant binding to attenuate BRAF V600 mutant tumor growth. In certain embodiments, this disclosure relates to methods of treating cancer comprising administering an effective amount of an agent to a subject in need thereof, wherein the agent is dehydroacetic acid, derivative, prodrug, or salt thereof.
    Type: Grant
    Filed: April 17, 2019
    Date of Patent: October 6, 2020
    Assignees: Emory University, The United States Government as Represented by the Department of Veterans Affairs
    Inventors: Jing Chen, Jack Arbiser, Brian Pollack, Siyuan Xia
  • Patent number: 10792356
    Abstract: In certain embodiments, the disclosure relates to the polynucleotide sequences of respiratory syncytial virus (RSV). In certain embodiments, the disclosure relates to isolated or recombinant nucleic acids and polypeptides comprising desirable nucleic acid sequences and mutations disclosed herein. In certain embodiments, isolated or recombinant RSV comprising the nucleic acids and polypeptides disclosed herein (e.g., attenuated recombinant RSV) are also provided, as are immunogenic compositions including such nucleic acids, polypeptides, and RSV genomes that are suitable for use as vaccines. Attenuated or killed RSV containing these nucleic acids and mutation in the form of copied nucleic acids (e.g., cDNAs) are also contemplated.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: October 6, 2020
    Assignees: Emory University, Children's Healthcare of Atlanta, Inc.
    Inventors: Martin L. Moore, Jia Meng, Anne Hotard, Elizabeth Littauer, Christopher C. Stobart